Project Grant R01CA290858
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$429K
Federal Agency
National Cancer Institute
Awardee
Purdue University (YRXVL4JYCEF5)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
This $230,711 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to elucidate the role of the BRD9 chromatin-remodeling protein in promoting an immunosuppressive tumor microenvironment that contributes to resistance to hedgehog inhibitor therapies in basal cell carcinomas. The funded research, conducted by the Trustees of Columbia University, will utilize CRISPR/Cas9 gene editing and mouse models to...
This $217,388 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to develop a directed evolution platform to create improved RNA methyltransferase (MTase) enzymes. The goal is to evolve MTases with enhanced catalytic efficiency and reduced sequence biases to enable more precise installation of the N6-methyladenosine (m6A) RNA modification, which plays important roles in cancer biology. The funded project will leverage in vitro...
This $572,254 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) supports Purdue University's efforts to identify small molecule inhibitors of the PLCG1 and PLCG2 enzymes. The key products and services to be delivered under this 3-year award include:
Employing high-throughput screening assays with newly developed fluorescent substrates to screen 200,000 compounds against PLCG1 and PLCG2 and identify primary hit molecules.
Validating...
This $563,663 federal Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to the University of Southern California (USC) to identify and characterize small molecule inhibitors of the Polycomb Repressive Complex 1 (PRC1) and PRC2 chromatin regulatory complexes. The goal is to discover new therapeutic approaches for cancers dependent on EZH2, a PRC2 subunit that is overexpressed or hyperactive in about 1-2% of all...
This federal Project Grant award, totaling $552,763, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania.
The grant funds research aimed at assessing the therapeutic potential of newly developed KAT6 inhibitors (KAT6is) as monotherapy and in combination with targeted therapy drugs for the treatment of high-grade...
The National Cancer Institute (NCI) awarded a $386,781 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to Hobart & William Smith Colleges to conduct multidisciplinary research on developing novel heterocyclic tubulin polymerization inhibitors as potential cancer treatments. The project aims to characterize previously identified tubulin-binding compounds, employ rational drug design to identify new heterocyclic tubulin inhibitors, and apply innovative synthetic...
The federal Project Grant award of $393,943 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research aimed at defining the cellular and biochemical mechanisms that can be exploited to improve the efficacy and toxicity profile of poly (ADP-ribose) polymerase inhibitors (PARPi) for BRCA-mutant cancers. The primary award recipient, Washington University, will lead investigations into how the loss of the nucleosome sliding...
This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents.
The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...
This Project Grant from the National Institutes of Health's National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), provides $900,000 to Midwestern University from September 2022 through August 2025. The grant funds research to characterize novel protein-protein interactions within Polycomb Repressive Complex 1 (PRC1) and investigate their role in the selective assembly of functionally distinct PRC1 complexes. PRC1 epigenetically regulates chromatin and improper...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $942,442 in funding to the Dana-Farber Cancer Institute, Inc. over the period of September 1, 2024 to August 31, 2031. The goal of this research is to identify the mechanisms driving rapid evolution of cancer genomes, particularly through processes like chromothripsis and chromoplexy. The project will leverage single-cell genomics methods developed by the...